The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: as-needed treatment in allergic rhinitis

Jean Bousquet; Mondher Toumi; Bernardo Sousa-Pinto; Josep M. Anto; Anna Bedbrook; Wienczyslawa Czarlewski; Arunas Valiulis; Ignacio J. Ansotegui; Sinthia Bosnic-Anticevich; Luisa Brussino; G. Walter Canonica; Lorenzo Cecchi; Ivan Cherrez-Ojeda; Tomas Chivato; Elísio M. Costa; Alvaro A. Cruz; Stefano Del Giacco; Joao A. Fonseca; Bilun Gemicioglu; Tari Haahtela; Juan Carlos Ivancevich; Marek Jutel; Igor Kaidashev; Ludger Klimek; Violeta Kvedariene; Piotr Kuna; Désirée E. Larenas-Linnemann; Brian Lipworth; Mario Morais-Almeida; Joaquim Mullol; Nikolaos G. Papadopoulos; Vincenzo Patella; Nhân Pham-Thi; Frederico S. Regateiro; Philip W. Rouadi; Boleslaw Samolinski; Aziz Sheikh; Luis Taborda-Barata; Maria Teresa Ventura; Arzu Yorgancioglu; Mihaela Zidarn; Torsten Zuberbier

doi:10.1016/j.jaip.2022.07.020

The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: as-needed treatment in allergic rhinitis

Jean Bousquet (Lead / Corresponding author), Mondher Toumi, Bernardo Sousa-Pinto, Josep M. Anto, Anna Bedbrook, Wienczyslawa Czarlewski, Arunas Valiulis, Ignacio J. Ansotegui, Sinthia Bosnic-Anticevich, Luisa Brussino, G. Walter Canonica, Lorenzo Cecchi, Ivan Cherrez-Ojeda, Tomas Chivato, Elísio M. Costa, Alvaro A. Cruz, Stefano Del Giacco, Joao A. Fonseca, Bilun Gemicioglu, Tari HaahtelaJuan Carlos Ivancevich, Marek Jutel, Igor Kaidashev, Ludger Klimek, Violeta Kvedariene, Piotr Kuna, Désirée E. Larenas-Linnemann, Brian Lipworth, Mario Morais-Almeida, Joaquim Mullol, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham-Thi, Frederico S. Regateiro, Philip W. Rouadi, Boleslaw Samolinski, Aziz Sheikh, Luis Taborda-Barata, Maria Teresa Ventura, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

193 Downloads (Pure)

Abstract

Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.

Original language	English
Pages (from-to)	2878-2888
Number of pages	11
Journal	The Journal of Allergy and Clinical Immunology: In Practice
Volume	10
Issue number	11
Early online date	4 Aug 2022
DOIs	https://doi.org/10.1016/j.jaip.2022.07.020
Publication status	Published - Nov 2022

Keywords

Allergic rhinitis
MASK-air
Repurposing
Treatment
Value-added medicine

ASJC Scopus subject areas

Immunology and Allergy

Access to Document

10.1016/j.jaip.2022.07.020Licence: Elsevier User Licence

Author Accepted ManuscriptAccepted author manuscript, 0.99 MBLicence: CC BY-NC-ND

Cite this

Bousquet, J., Toumi, M., Sousa-Pinto, B., Anto, J. M., Bedbrook, A., Czarlewski, W., Valiulis, A., Ansotegui, I. J., Bosnic-Anticevich, S., Brussino, L., Canonica, G. W., Cecchi, L., Cherrez-Ojeda, I., Chivato, T., Costa, E. M., Cruz, A. A., Del Giacco, S., Fonseca, J. A., Gemicioglu, B., ... Zuberbier, T. (2022). The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: as-needed treatment in allergic rhinitis. The Journal of Allergy and Clinical Immunology: In Practice, 10(11), 2878-2888. https://doi.org/10.1016/j.jaip.2022.07.020

@article{a9b60b24953c45de96f07ab170244f8b,

title = "The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: as-needed treatment in allergic rhinitis",

abstract = "Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.",

keywords = "Allergic rhinitis, MASK-air, Repurposing, Treatment, Value-added medicine",

author = "Jean Bousquet and Mondher Toumi and Bernardo Sousa-Pinto and Anto, {Josep M.} and Anna Bedbrook and Wienczyslawa Czarlewski and Arunas Valiulis and Ansotegui, {Ignacio J.} and Sinthia Bosnic-Anticevich and Luisa Brussino and Canonica, {G. Walter} and Lorenzo Cecchi and Ivan Cherrez-Ojeda and Tomas Chivato and Costa, {El{\'i}sio M.} and Cruz, {Alvaro A.} and {Del Giacco}, Stefano and Fonseca, {Joao A.} and Bilun Gemicioglu and Tari Haahtela and Ivancevich, {Juan Carlos} and Marek Jutel and Igor Kaidashev and Ludger Klimek and Violeta Kvedariene and Piotr Kuna and Larenas-Linnemann, {D{\'e}sir{\'e}e E.} and Brian Lipworth and Mario Morais-Almeida and Joaquim Mullol and Papadopoulos, {Nikolaos G.} and Vincenzo Patella and Nh{\^a}n Pham-Thi and Regateiro, {Frederico S.} and Rouadi, {Philip W.} and Boleslaw Samolinski and Aziz Sheikh and Luis Taborda-Barata and Ventura, {Maria Teresa} and Arzu Yorgancioglu and Mihaela Zidarn and Torsten Zuberbier",

note = "Copyright Information: {\textcopyright} 2022 American Academy of Allergy, Asthma & Immunology.",

year = "2022",

month = nov,

doi = "10.1016/j.jaip.2022.07.020",

language = "English",

volume = "10",

pages = "2878--2888",

journal = "The Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "11",

}

Bousquet, J, Toumi, M, Sousa-Pinto, B, Anto, JM, Bedbrook, A, Czarlewski, W, Valiulis, A, Ansotegui, IJ, Bosnic-Anticevich, S, Brussino, L, Canonica, GW, Cecchi, L, Cherrez-Ojeda, I, Chivato, T, Costa, EM, Cruz, AA, Del Giacco, S, Fonseca, JA, Gemicioglu, B, Haahtela, T, Ivancevich, JC, Jutel, M, Kaidashev, I, Klimek, L, Kvedariene, V, Kuna, P, Larenas-Linnemann, DE, Lipworth, B, Morais-Almeida, M, Mullol, J, Papadopoulos, NG, Patella, V, Pham-Thi, N, Regateiro, FS, Rouadi, PW, Samolinski, B, Sheikh, A, Taborda-Barata, L, Ventura, MT, Yorgancioglu, A, Zidarn, M & Zuberbier, T 2022, 'The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: as-needed treatment in allergic rhinitis', The Journal of Allergy and Clinical Immunology: In Practice, vol. 10, no. 11, pp. 2878-2888. https://doi.org/10.1016/j.jaip.2022.07.020

The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: as-needed treatment in allergic rhinitis. / Bousquet, Jean (Lead / Corresponding author); Toumi, Mondher; Sousa-Pinto, Bernardo et al.
In: The Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, No. 11, 11.2022, p. 2878-2888.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines

T2 - as-needed treatment in allergic rhinitis

AU - Bousquet, Jean

AU - Toumi, Mondher

AU - Sousa-Pinto, Bernardo

AU - Anto, Josep M.

AU - Bedbrook, Anna

AU - Czarlewski, Wienczyslawa

AU - Valiulis, Arunas

AU - Ansotegui, Ignacio J.

AU - Bosnic-Anticevich, Sinthia

AU - Brussino, Luisa

AU - Canonica, G. Walter

AU - Cecchi, Lorenzo

AU - Cherrez-Ojeda, Ivan

AU - Chivato, Tomas

AU - Costa, Elísio M.

AU - Cruz, Alvaro A.

AU - Del Giacco, Stefano

AU - Fonseca, Joao A.

AU - Gemicioglu, Bilun

AU - Haahtela, Tari

AU - Ivancevich, Juan Carlos

AU - Jutel, Marek

AU - Kaidashev, Igor

AU - Klimek, Ludger

AU - Kvedariene, Violeta

AU - Kuna, Piotr

AU - Larenas-Linnemann, Désirée E.

AU - Lipworth, Brian

AU - Morais-Almeida, Mario

AU - Mullol, Joaquim

AU - Papadopoulos, Nikolaos G.

AU - Patella, Vincenzo

AU - Pham-Thi, Nhân

AU - Regateiro, Frederico S.

AU - Rouadi, Philip W.

AU - Samolinski, Boleslaw

AU - Sheikh, Aziz

AU - Taborda-Barata, Luis

AU - Ventura, Maria Teresa

AU - Yorgancioglu, Arzu

AU - Zidarn, Mihaela

AU - Zuberbier, Torsten

PY - 2022/11

Y1 - 2022/11

N2 - Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.

AB - Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.

KW - Allergic rhinitis

KW - MASK-air

KW - Repurposing

KW - Treatment

KW - Value-added medicine

UR - http://www.scopus.com/inward/record.url?scp=85138811635&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2022.07.020

DO - 10.1016/j.jaip.2022.07.020

M3 - Article

C2 - 35934308

SN - 2213-2198

VL - 10

SP - 2878

EP - 2888

JO - The Journal of Allergy and Clinical Immunology: In Practice

JF - The Journal of Allergy and Clinical Immunology: In Practice

IS - 11

ER -

The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: as-needed treatment in allergic rhinitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this